Blair William & Co. IL decreased its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 5.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 251,255 shares of the medical equipment provider's stock after selling 15,263 shares during the period. Blair William & Co. IL owned about 0.17% of ResMed worth $57,459,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its stake in ResMed by 12.2% during the third quarter. Thrivent Financial for Lutherans now owns 6,952 shares of the medical equipment provider's stock worth $1,697,000 after acquiring an additional 755 shares in the last quarter. Intech Investment Management LLC acquired a new position in ResMed during the 3rd quarter worth approximately $244,000. Cerity Partners LLC lifted its stake in ResMed by 82.0% in the 3rd quarter. Cerity Partners LLC now owns 13,686 shares of the medical equipment provider's stock valued at $3,341,000 after purchasing an additional 6,167 shares during the last quarter. Summit Trail Advisors LLC boosted its position in ResMed by 15.6% in the third quarter. Summit Trail Advisors LLC now owns 1,497 shares of the medical equipment provider's stock valued at $365,000 after buying an additional 202 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of ResMed by 6.2% during the third quarter. Fisher Asset Management LLC now owns 26,727 shares of the medical equipment provider's stock worth $6,525,000 after buying an additional 1,563 shares during the last quarter. 54.98% of the stock is owned by institutional investors.
ResMed Trading Down 0.4 %
RMD traded down $0.85 during trading on Tuesday, hitting $223.01. The company's stock had a trading volume of 182,441 shares, compared to its average volume of 940,920. The firm has a market capitalization of $32.75 billion, a P/E ratio of 26.33, a PEG ratio of 1.53 and a beta of 0.74. ResMed Inc. has a twelve month low of $172.19 and a twelve month high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The stock's fifty day moving average price is $233.37 and its 200-day moving average price is $237.83.
ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Analysts anticipate that ResMed Inc. will post 9.47 EPS for the current year.
ResMed Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were paid a $0.53 dividend. The ex-dividend date was Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.95%. ResMed's dividend payout ratio is presently 25.03%.
Insider Activity at ResMed
In other news, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now owns 77,218 shares in the company, valued at $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at approximately $2,327,289.75. This represents a 50.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,940 shares of company stock valued at $9,164,385 in the last three months. Corporate insiders own 0.71% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on RMD. Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. Piper Sandler upped their price objective on ResMed from $252.00 to $260.00 and gave the company a "neutral" rating in a research note on Friday, January 31st. KeyCorp lifted their target price on shares of ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. UBS Group upgraded shares of ResMed from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 31st. Finally, Stifel Nicolaus reduced their price objective on shares of ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $249.73.
Check Out Our Latest Stock Report on ResMed
ResMed Company Profile
(
Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
See Also
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
